BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35285011)

  • 1. A comparative clinicopathological and survival analysis of synchronous bilateral breast cancers.
    Bai Y; Lu J; Wu H; Wang J; Niu Y; Pang J; Wu S; Liu Y; Liang Z
    Histol Histopathol; 2022 Aug; 37(8):791-802. PubMed ID: 35285011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.
    Liu Y; Yu T
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11181-11191. PubMed ID: 37354223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study.
    Guan X; Xu G; Shi A; Zou Y; Zhan Y; Fan Z; Dong Y
    Medicine (Baltimore); 2020 Dec; 99(50):e23487. PubMed ID: 33327281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and prognosis of bilateral breast cancer: a single-center cohort study based on Chinese data.
    Hong C; Zheng Y; Geng R; Hu H; Zhong Y; Guan Q; Zhang Y; Li X
    Ann Transl Med; 2022 Jul; 10(13):742. PubMed ID: 35957718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
    Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
    Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma.
    Matsuo K; Fukutomi T; Akashi-Tanaka S; Hasegawa T; Tsuda H
    Breast Cancer; 2002; 9(2):127-33. PubMed ID: 12016392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes.
    Micello D; Bossi A; Marando A; Dainese E; Sessa F; Capella C
    Virchows Arch; 2017 Jul; 471(1):13-21. PubMed ID: 28550498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
    Zhang B; Liu FF; Ma YJ; Gu F
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
    Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognosis of synchronous bilateral breast cancers].
    Niu YR; Wu HW; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):435-440. PubMed ID: 32392926
    [No Abstract]   [Full Text] [Related]  

  • 19. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
    Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
    Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Tanaka K; Masuda N; Hayashi N; Sagara Y; Hara F; Kadoya T; Matsui A; Miyazaki C; Shien T; Tokunaga E; Hayashi T; Niikura N; Maeda S; Komoike Y; Bando H; Kanbayashi C; Iwata H
    Breast Cancer; 2021 Jul; 28(4):896-903. PubMed ID: 33599914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.